Document text
Principal Investigator: Lanying Du
Organization: NEW YORK BLOOD CENTER
Fiscal Year: 2020
Award: $832,650
Funding agency: National Institute of Allergy and Infectious Diseases
Summary
A novel coronavirus (CoV), SARS-CoV-2, is causing global pandemics with growing numbers of daily cases
and deaths. SARS-CoV-2 is closely related to SARS-CoV, which caused the 2002-2003 SARS epidemic, and
less closely related to MERS-CoV, which causes a high mortality rate in infected patients. No therapeutic
agents or vaccines have been approved to control the infections of these CoVs in humans, calling for
immediate efforts to develop effective countermeasures. The CoV spike (S) proteins are important targets for
therapeutics. They guide virus entry into host cells by binding to a host receptor through their S1 subunits and
fusing the viral and host cell membranes through their S2 subunits. The S1 subunits contain a receptor-binding
domain (RBD). Both RBD and S2 region of S protein can elicit neutralizing antibodies. The RBD is the major
target to induce potent neutralizing antibodies, but it diverges among different CoVs, whereas the S2 region of
S protein is more conserved among different CoVs. Nanobodies (Nbs) are single-domain antibodies derived
from camelid antibodies. They are emerging as novel therapeutic agents, numbers of which have been
approved or tested in clinical trials to prevent and treat other human diseases. Nbs possess many unique
advantages as therapeutic agents: they have high physical and chemical stabilities, excellent tissue
penetration capability (superior pharmacokinetics), easy expression with great production yields, and
robustness for storage and transportation. Moreover, Nbs can potentially recognize epitopes (e.g. hidden or
partially hidden epitopes) that are not accessible to conventional antibodies. In this proposal, we will design
and develop Nbs as therapeutic agents against SARS-CoV-2 and other pathogenic human CoVs using phage
display and structural biology as guiding tools. We propose to develop highly efficacious Nbs against SARS-
CoV-2 to stop the current COVID-19 pandemic and also broad-spectrum neutralizing Nbs targeting future CoV
infections. We have established Nb libraries and identified several neutralizing Nbs targeting the RBDs of
SARS-CoV and MERS-CoV, providing a solid foundation for the proposed studies. In our previous work, we
extensively characterized the structures and functions of MERS-CoV and SARS-CoV S proteins, and we have
recently characterized the RBD of SARS-CoV-2 and solved its structure in complex with viral receptor, paving
the way for rapid screening and identification of SARS-CoV-2 S protein-based Nbs. The specific aims of this
proposal are to: 1) develop highly efficacious Nbs targeting SARS-CoV-2 S (RBD/S2) protein; develop broad-
spectrum Nbs against CoV infections, 2) characterize these CoV S-targeting Nbs, and 3) evaluate in vivo
efficacy of these Nbs against SARS-CoV-2 and other CoV infections. Overall, this proposal will develop
highly efficacious Nbs targeting SARS-CoV-2 S protein, aiming to stop the current COVID-19 pandemic. It will
also develop broad-spectrum Nbs targeting future CoV infections. This proposal has important implications for
combating pathogenic coronaviruses and neutralizing their threat to human health.
Terms: <2019 novel coronavirus><2019-nCoV><Affinity><Angiotensin Converting Enzyme><Angiotensin I-Converting Enzyme><Animal Model><Animal Models and Related Studies><Antibodies><Antigenic Determinants><Antigens><Binding><Binding Determinants><Body Tissues><CD143 Antigens><COVID-19><COVID-19 epidemic><COVID-19 pandemic><COVID19><COVID19 epidemic><COVID19 pandemic><Cancers><Carboxycathepsin><Cell Body><Cell Culture Techniques><Cell membrane><Cells><Cessation of life><Clinical Trials><CoV S protein><CoV emergence><CoV glycoprotein S><CoV spike glycoprotein><CoV spike protein><Complex><Coronaviridae><Coronaviridae Infections><Coronavirus><Coronavirus Infections><Coronavirus glycoprotein S><Coronavirus spike protein><Cryo-electron Microscopy><Cryoelectron Microscopy><Cytoplasmic Membrane><Death><Development><Dipeptidyl Aminopeptidases><Dipeptidyl Peptidase A><Dipeptidyl Peptidases><Dipeptidylpeptide Hydrolases><Drug Kinetics><Drug or chemical Tissue Distribution><Electron Cryomicroscopy><Electrons><Engineering><Epidemic><Epitopes><Evaluation><Foundations><Future><Goals><Guidelines><HCoV><Half-Life><Health><Human><Infection Control><Kininase A><Kininase II><Libraries><Life><MERS corona virus><MERS coronavirus><MERS virus><MERS-CoV><Malignant Neoplasms><Malignant Tumor><Membrane><Microscopic><Middle East Respiratory Syndrome Corona Virus><Middle East Respiratory Syndrome Coronavirus><Middle East Respiratory Syndrome Virus><Middle East Respiratory Syndrome-CoV><Middle Eastern Respiratory Syndrome Corona virus><Middle Eastern Respiratory Syndrome Coronavirus><Middle Eastern Respiratory Syndrome Virus><Middle Eastern Respiratory Syndrome-CoV><Modern Man><Molecular Interaction><Negative Beta Particle><Negatrons><Pathogenesis><Pathogenicity><Patients><Penetration><Peptidyl-Dipeptidase A><Phage Display><Pharmacokinetics><Phase><Plasma Membrane><Position><Positioning Attribute><Production><Proteins><Receptor Protein><Research><Roentgen Rays><SARS><SARS Virus><SARS corona virus><SARS coronavirus><SARS coronavirus disease><SARS-Associated Coronavirus><SARS-CoV><SARS-CoV disease><SARS-CoV-2><SARS-CoV2><SARS-Related Coronavirus><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-related coronavirus 2><Severe Acute Respiratory Syndrome><Severe Acute Respiratory Syndrome CoV disease><Severe Acute Respiratory Syndrome Virus><Severe Acute Respiratory Syndrome corona virus><Severe Acute Respiratory Syndrome coronavirus><Severe Acute Respiratory Syndrome coronavirus disease><Severe acute respiratory syndrome coronavirus 2><Solid><Solubility><Structure><Surface><Techniques><Testing><Therapeutic><Therapeutic Agents><Tissue Distribution><Tissues><Toxic effect><Toxicities><Transportation><Treatment Efficacy><Vaccine Design><Viral><Viral Diseases><Viral Receptor><Virus><Virus Diseases><Virus Receptors><Work><Wuhan coronavirus><X-Radiation><X-Ray Radiation><X-ray><Xray><base><candidate selection><cell culture><chemical stability><combat><corona virus><corona virus disease 2019><corona virus disease 2019 epidemic><corona virus disease 2019 pandemic><coronavirus S protein><coronavirus disease 2019><coronavirus disease 2019 epidemic><coronavirus disease 2019 pandemic><coronavirus emergence><coronavirus spike glycoprotein><cryo-EM><cryoEM><design><designing><developmental><effective therapy><effective treatment><emergent CoV><emergent coronavirus><emerging CoV><emerging coronavirus><global health><human CoV><human corona virus><human coronavirus><human disease><immunogen><in vivo><in vivo evaluation><in vivo testing><intervention efficacy><malignancy><membrane structure><model of animal><model organism><mortality><mouse model><murine model><nCoV><nanobodies><nanobody><neoplasm/cancer><neutralizing antibody><new CoV><new coronavirus><new drug treatments><new drugs><new therapeutics><new therapy><next generation therapeutics><non-human primate><nonhuman primate><novel><novel CoV><novel coronavirus><novel drug treatments><novel drugs><novel therapeutics><novel therapy><pandemic><pandemic disease><pathogenic virus><plasmalemma><prevent><preventing><prophylactic><receptor><receptor binding><receptor bound><screening><sdAb><severe acute respiratory syndrome-CoV><single domain antibodies><structural biology><targeted drug therapy><targeted drug treatments><targeted therapeutic><targeted therapeutic agents><targeted therapy><targeted treatment><therapeutic efficacy><therapeutic vaccine><therapeutically effective><therapy efficacy><tool><treatment vaccines><vaccine for the treatment><vaccine for treatment><viral infection><viral pathogen><virus infection><virus-induced disease>